
### [NCIT:C3721](http://purl.obolibrary.org/obo/NCIT_C3721)
**Label:** Lymphomatoid Papulosis

**Subclasses:** [NCIT:C139014](http://purl.obolibrary.org/obo/NCIT_C139014) (Type D Lymphomatoid Papulosis), [NCIT:C139015](http://purl.obolibrary.org/obo/NCIT_C139015) (Type E Lymphomatoid Papulosis), [NCIT:C7197](http://purl.obolibrary.org/obo/NCIT_C7197) (Type A Lymphomatoid Papulosis), [NCIT:C7199](http://purl.obolibrary.org/obo/NCIT_C7199) (Type C Lymphomatoid Papulosis), [NCIT:C7198](http://purl.obolibrary.org/obo/NCIT_C7198) (Type B Lymphomatoid Papulosis), 

**Class expressions from DL-Learner:**

- [NCIT:C39715](http://purl.obolibrary.org/obo/NCIT_C39715) (CD30-Positive Neoplastic Cells Present) 53.57%
- [NCIT:C39626](http://purl.obolibrary.org/obo/NCIT_C39626) (Epidermotropic Lymphocytic Infiltrate) 53.57%
- [NCIT:C39589](http://purl.obolibrary.org/obo/NCIT_C39589) (Angioinvasion) 53.57%
- [NCIT:C38721](http://purl.obolibrary.org/obo/NCIT_C38721) (Nuclear Pleomorphism) 53.57%
- [NCIT:C36156](http://purl.obolibrary.org/obo/NCIT_C36156) (Favorable Clinical Outcome) 53.57%
- [NCIT:C36105](http://purl.obolibrary.org/obo/NCIT_C36105) (Indolent Clinical Course) 53.57%
- [NCIT:C35980](http://purl.obolibrary.org/obo/NCIT_C35980) (Chronic Inflammatory Infiltrate) 53.57%
- Error10 53.57%
- [NCIT:C35979](http://purl.obolibrary.org/obo/NCIT_C35979) (Acute Inflammatory Infiltrate) and (not ([NCIT:C35981](http://purl.obolibrary.org/obo/NCIT_C35981) (Eosinophilic Infiltrate))) 53.57%
- Thing 53.04%
- [NCIT:C35978](http://purl.obolibrary.org/obo/NCIT_C35978) (Inflammatory Infiltrate) 42.50%
- [NCIT:C35983](http://purl.obolibrary.org/obo/NCIT_C35983) (Lymphocytic Infiltrate) 38.93%
- [NCIT:C35979](http://purl.obolibrary.org/obo/NCIT_C35979) (Acute Inflammatory Infiltrate) 38.93%
- [NCIT:C35939](http://purl.obolibrary.org/obo/NCIT_C35939) (Tumor Vascular Invasion) 38.93%
- [NCIT:C35979](http://purl.obolibrary.org/obo/NCIT_C35979) (Acute Inflammatory Infiltrate) and (not ([NCIT:C39966](http://purl.obolibrary.org/obo/NCIT_C39966) (Ovarian Sertoli-Stromal Cell Tumor))) 38.93%


